

10-22-04

JFC

Express Mail No. EV519865679US

INFORMATION DISCLOSURE STATEMENT		
Address to:	Attorney Docket	CELL-004CON2
Commissioner for Patents	First Named Inventor	HENDERSON, DANIEL R.
P.O. Box 1450	Application Number	10/822,873
Alexandria, VA 22313-1450	Confirmation No.	3173
	Filing Date	April 13, 2004
	Group Art Unit	1632
	Examiner Name	
	Title:	"TISSUE SPECIFIC ADENOVIRAL VECTORS"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

**All of the references identified herein of which copies are not provided were disclosed in parent application serial number 09/732,169 filed 12/6/2000 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).**

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. CELL-004CON2 may be charged thereon.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: October 18, 2004  
By: Pamela J. Sherwood  
Pamela J. Sherwood  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231



Please type a plus sign (+) inside this box → +

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

		Application Number	10/822,873
		Filing Date	April 13, 2004
		First Named Inventor	HENDERSON, DANIEL R.
		Group Art Unit	1632
		Examiner Name	
Total Number of Pages in This Submission	10 + refs.	Attorney Docket Number	CELL-004CON2

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i>	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Form PTO/SB/08A
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Copies of cited references
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)	3. Postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		


### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36,677 BOICEVIC, FIELD & FRANCIS, LLP
Signature	
Date	October 18, 2004

### EXPRESS MAIL LABEL NO. EV519865679US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Please type a plus sign (+) inside this box →

EV519865679US

PTO/SB/08A (08-0)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/822,873
				Filing Date	April 13, 2004
				First Named Inventor	Henderson et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	8	Attorney Docket Number	CELL-004CON2

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	1	2001-0006633		KIRN, D.	07/05/2001	
	2	2001-0053352		YU et al.	12/20/2001	
	3	2001-0053768		GREGORY, et al.	12/20/2001	
	4	2002-0120117		YU et al.	08/29/2002	
	5	2002-0136707		YU et al.	09/26/2002	
	6	2002-0192187		MCCLELLAND et al.	12/19/2002	
	7	2003-0026792		LAMPARSKI et al.	02/06/2003	
	8	2003-0039633		YU et al.	02/27/2003	
	9	2003-0068307		YU et al.	04/10/2003	
	10	2003-0104624		GORZIGLIA, et al.	02/22/2002	
	11	2003-0104625		CHENG et al.	06/05/2003	
	12	2003-0152553		LITTLE et al.	08/14/2003	
	13	5,112,767		ROY-BURMAN, et al.	05/12/1992	
	14	5,302,698		MORINAGA et al.	04/1994	
	15	5,324,664		NUNBERG, et al.	06/28/1994	
	16	5,358,866		MULLEN et al.	10/25/1994	
	17	5,416,017		BURTON et al.	05/16/1995	
	18	5,569,667		GROVE et al.	10/1996	
	19	5,585,096		MARTUZA et al.	12/17/1996	
	20	5,601,818		FREEMAN et al.	02/11/1997	
	21	5,624,830		MULLEN et al.	04/29/1997	
	22	5,631,236		WOO et al	05/20/1997	
	23	5,648,478		HENDERSON	07/1997	
	24	5,672,344		KELLEY, et al.	09/30/1997	
	25	5,677,178		MCCORMICK, F.	10/14/1997	
	26	5,698,443		HENDERSON, et al.	12/16/1997	
	27	5,707,618		ARMENTANO, et al.	01/13/1998	
	28	5,728,379		MARTUZA et al.	03/17/1998	
	29	5,747,469		ROTH, et al.	05/05/1998	
	30	5,770,442		WICKHAM et al.	06/23/1998	
	31	5,801,029		MCCORMICK, F.	09/01/1998	
	32	5,804,407		TAMAOKI et al.	09/08/1998	
	33	5,830,686		HENDERSON, D.	11/03/1998	
	34	5,837,511		FALCK-PEDERSON, et al.	11/17/1998	

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	
Examiner Name	

Sheet

2

of

8

Attorney Docket Number

CELL-004CON2

35	5,846,945	MCCORMICK, F.	12/08/1998	
36	5,856,181	MCCORMICK, F.	01/05/1999	
37	5,871,726	HENDERSON, et al.	02/16/1999	
38	5,994,128	FALLAUX, et al.	11/30/1999	
39	5,998,205	HALLENBECK et al.	12/07/1999	
40	6,051,417	HALLENBECK et al.	04/18/2000	
41	6,057,299	HENDERSON, D.	05/02/2000	
42	6,080,578	BISCHOFF, et al.	06/27/2000	
43	6,133,243	KIRN, D.	10/17/2000	
44	6,136,792	HENDERSON, D.	10/24/2000	
45	6,197,293	HENDERSON, et al.	03/06/2001	
46	6,254,862	LITTLE, et al.	07/03/2001	
47	6,271,207	CRISTIANO, et al.	08/07/2001	
48	6,296,845	SAMPSON-JOHANNES, et al.	10/02/2001	
49	6,297,219	NABEL, et al.	10/02/2001	
50	6,432,700	HENDERSON, et al.	08/13/2002	
51	6,436,394	HENDERSON, et al.	08/20/2002	
52	6,495,130	HENDERSON, et al.	12/17/2002	
53	6,551,587	HALLENBECK	04/22/2003	
54	6,585,968	LITTLE et al.	07/01/2003	
55	6,638,762	CHANG et al.	10/28/2003	
56	6,676,935	HENDERSON et al.	01/13/2004	
57	6,692,736	YU et al.	02/17/04	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
58		WO 90/05180				05/17/1990		
59		WO 92/03563				03/05/1992		
60		WO 92/05262				04/02/1992		
61		WO 94/03594				02/1994		
62		WO 94/18992				09/01/1994		
63		WO 94/28152				12/1994		
64		WO 95/05835				03/02/1995		
65		WO 95/11984				05/1995		
66		WO 95/14100				05/1995		
67		WO 95/14102				05/26/1995		
68		WO 95/19434				07/20/1995		
69		WO 96/14875				05/23/1996		

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	
Examiner Name	

Sheet

3

of 8

Attorney Docket Number

CELL-004CON2

70	WO 96/16676	06/1996
71	WO 96/17053	06/06/1996
72	WO 96/18418	06/20/1996
73	WO 96/34969	11/07/1996
74	WO 97/01358	01/16/1997
75	WO 97/04805	02/13/1997
76	WO 97/48277	12/24/1997
77	WO 98/13508	04/02/1998
78	WO 98/27207	06/25/1998
79	WO 98/28469	07/02/1998
80	WO 98/35028	08/13/1998
81	WO 98/39464	09/11/1998
82	WO 98/39465	09/11/1998
83	WO 98/39466	09/11/1998
84	WO 98/39467	09/11/1998
85	WO 99/06576	02/11/1999
86	WO 99/28469	06/10/1999
87	WO 99/55831	11/04/1999
88	WO 99/59604	11/25/1999
89	WO 00/03029	01/20/2000
90	WO 00/15820	03/20/2000
91	WO 00/22124	04/20/2000
92	WO 00/29599	05/25/2000
93	WO 00/31286	06/02/2000
94	WO 00/39319	07/06/2000
95	WO 00/46355	08/10/2000
96	WO 00/47768	08/17/2000
97	WO 00/56909	09/28/2000
98	WO 00/67576	11/16/2000
99	WO 00/70071	11/23/2000
100	WO 01/02540	01/11/2001
101	WO 01/04282	01/18/2001
102	WO 01/04334	01/18/2001
103	WO 01/23004	04/05/2001
104	WO 01/36650	05/25/2001
105	WO 01/72341	10/04/2001
106	WO 01/73093	10/04/2001
107	WO 02/68627	09/06/2002
108	WO 04/42025	05/21/2004

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	109	ABE, M. et al., J. Cell. Physiol. 143:226-231 (1990)	

27

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

8

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	
Examiner Name	

Attorney Docket Number

CELL-004CON2

110	ABE, M. et al., Proc. Natl. Sci. Acad. USA, Biochemistry, 90:282-286 (1993)
111	ARMITAGE, J., Blood 92(12):4491-4508 (December 1998)
112	AUSUBEL, F.M. et al., Current Protocols in Molecular Biology, Table 7.7.1, Sections 7.7.18-19, Supplement 30 (1987)
113	AUSUBEL, F.M. et al., Current Protocols in Molecular Biology, Volume I, John Wiley & Sons, Inc., Table of Contents, Supplement 30, 39, pp. iii-xii (1995)
114	BETT, A. et al., J. of Virology 67(10): 5911-5921 (1993)
115	BLAESE, R. et al., Eur. J. Cancer 30A: 1190-1193 (August 1994)
116	BRIDGE, E. et al., J. Virol. 63(2):631-638 (1989)
117	BRISTOL, et al., Abstract No. P2, presented at The 10 <sup>th</sup> Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002.
118	BRISTOL, et al., poster at the Keystone Symposia, Basic Aspects of Tumor Immunology, February 17-23, 2003.
119	BROOKES DE, Prostate 35(1):18-26 (Apr 1, 1998)
120	BRUDER, et al., Molecular and Cellular Biology 9(11):5143-5153 (Nov 1989).
121	CHANG, Y. et al., Cold Spring Harbor Gene Therapy Meeting, page 53 (1996)
122	CHARLESWORTH, C. et al., Urology 49(3):487-493 (1997)
123	CHIA, et al., Proceedings of the American Association for Cancer Research 43:1098-1099, abstract 5441 (March 2002).
124	CHIOCCA, E., Nature 2:938-950 (Dec 2002).
125	CHRIST, et al., Human Gene Therapy, 11:415-427 (Feb 10, 2000).
126	CLEUTJENS et al., Molecular Endocrinology 11(9):1256-1265, 1997.
127	CLEUTJENS et al., Molecular Endocrinology 11(2):148-161, 1997
128	CURIEL, et al., Proceedings of the American Association for Cancer Research 43:662, abstract 3287 (March 2002).
129	DARSON, M. et al., Urology 49(6):857-862 (1997)
130	DEMERS, et al., Proceedings of the American Association for Cancer Research 43:663, abstract 3291 (March 2002).
131	DEWESE, et al., Cancer Research, 61:7464-7472 (Oct 15, 2001)
132	DORONIN, et al., Journal of Virology, 75(7):3314-3324 (Apr 2001)
133	DORONIN, et al., Journal of Virology, 74(13):6147-6155 (July 2000)
134	DUQUE, et al., Cancer Gene Therapy, 6(6):554-563 (1999).
135	EISELEIN, et al., Cancer Research, 38:3817-3822 (1978)
136	ENNIST, D., abstract at the 4 <sup>th</sup> International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

<u>Application Number</u>	10/822,873
<u>Filing Date</u>	April 13, 2004
<u>First Named Inventor</u>	Henderson et al.
<u>Group Art Unit</u>	
<u>Examiner Name</u>	

Sheet

5

of

8

Attorney Docket Number

CELL-004CON2

29

137	ENNIST, D., Proceedings of the American Association for Cancer Research 43:1098, abstract 5437 (March 2002).
138	FALLAUX, et al., Human Gene Therapy, 9:1909-1917 (Sep 1, 1998).
139	FANG, et al., Journal of Virology, 71(6):4798-4803 (June 1997).
140	FRIEDMAN et al., Molecular and Cellular Biology, 6(11) 3791-3797, 1986
141	GANLY, et al., Clinical Cancer Research, 6:798-806 (March 2000)
142	GOODRUM, F. D., J. Virol. 71(1):548-561 (1997)
143	GOTOH, A. et al., Proceedings of the American Urological Association 153, 4 Supp. 308A, Abstract No. 320 (1995)
144	GOTOH, et al., J. Urol. 160(1):220-229 (July 1998)
145	GRAHAM, F. L., The Journal of General Virology 36(Part 1): 59-72 (1977)
146	GRAHAM, F, Journal of General Virology, 68:937-940(1987)
147	GRAND, R., Biochem. J. 241:25-38 (1987)
148	GREENBERG, N. et al., Molec. Endocrinol. 8(2): 230-239 (1994)
149	GROOTECLAES, M. et al., Cancer Res. 54:4193-4199 (1994)
150	HABIB, et al., Human Gene Therapy, 12:219-226 (February 10, 2001)
151	HALLENBECK, P.L., et al., Human Gene Therapy 10:1721-1733 (1999).
152	HEARING, et al., Cell, 33:695-703 (1983)
153	HEISE, et al., Cancer Gene Therapy, 6(6): 499-504 (1999)
154	HEISE, et al., Clinical Cancer Research, 6:4908-4914 (December 2000)
155	HEISE, et al., The Journal of Clinical Investigation, 105(7): 847-851 (April 2000)
156	HERMISTON, T., The Journal of Clinical Investigation, 105(9): 1169-1172 (May 2000)
157	HITT, M et al., Virology 179:667-678 (1990)
158	HORWITZ, M., Virology, 279:1-8 (January 5, 2001)
159	HUBER, B. et al., Adv. Drug. Delivery Reviews 17:279-292 (1995)
160	HUDSON, L. et al., J. Biol. Chem. 265(8): 4389-4393 (1990)
161	HUNG MIEN-CHIE et al., Gene 159:65-71 (1995)
162	IDO AKIO et al., Cancer Res. 55:3105-3109 (1995)
163	ILAN, et al., Proc. Natl. Acad. Sci. USA, 94:2587-2592 (March 1997)
164	ISHII SHUNSUKE et al., Proc. Natl. Acad. Sci. USA, Biochemistry 84:4374-4378 (1987)
165	JAKUBCZAK, et al., Molecular Therapy, 3(5): abstract 442 (May 2001)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	
Examiner Name	

Sheet

6

of

8

Attorney Docket Number

CELL-004CON2

166	JAKUBCZAK, et al., Molecular Therapy, 5(5): abstract No. 851 (March 2002)
167	JOHNSON, et al., Proceedings of the American Association for Cancer Research. 43:656. abstract No. 3257 (March 2002)
168	KANEKO, S. et al., Cancer Research 55:5283-5287 (Nov 1995)
169	KHURI, et al., Nature Medicine, 6(8): 879-885 (August 2000)
170	KIRN, D., Gene Therapy, 8:89-98 (January 2001)
171	KOVARIK, A. et al., J. Biol. Chem. 271(30): 18140-18147 (1996)
172	KOVARIK, A. et al., J. Biol. Chem. 268(13): 9917-9926 (1993)
173	KOVESDI, et al., Cell, 45:219-228 (April 25, 1986)
174	KRAJCSI, et al., Journal of Virology, 70(8): 4904-4913 (August 1996)
175	KUFE, D. et al., Hybridoma 3(3): 223-232 (1984)
176	KURIHARA, et al., The Journal of Clinical Investigation, 106(6): 763-771 (September 2000)
177	KWONG, et al., Chest, 112(5): 1332-1337 (November 1997)
178	LATHAM JP, Cancer Research 60(2): 334-341 (Jan 15, 2000)
179	LI, Y. et al. Cancer Research, Vol. 61, No. 17, pp: 6428-6436 (2001).
180	LI, et al., Proceedings of the American Association for Cancer Research, 43:858, abstract No. 4251 (March 2002)
181	LUNDWALL, A. et al., Biochim. Biophys. Res. Commun. 161(3): 1151-1159 (1989)
182	LUNDY, J. et al., Breast Cancer Res. Treat. 5:269-276 (1985)
183	LYONS, R., ASM Gene Therapy Conference, February 28, 2003, Banff, Alberta CA: oral presentation presented February 28, 2003
184	MABJEESH, et al., Endocrine-Related Cancer, 9:115-139 (June 2002)
185	MANOME, et al., Cancer Research, 54(20): 5408-5413 (October 15, 1994)
186	MILLER, et al., Human Gene Therapy, 8:803-815 (May 1, 1997).
187	MORRIS, B., Clin. Exp. Pharm. Physiol. 16:345-351 (1989)
188	MURTHA, P. et al., Biochem. 32(25): 6459-6464 (1993)
189	NEMUNAITIS, et al., Cancer Research, 60:6359-6366 (November 15, 2000)
190	OSAKI, T. et al., Cancer Research 54:5258-5261 (Oct 1994)
191	PAIELLI, et al., Molecular Therapy, 1(3): 263-274 (March 2000)
192	PANG, S. et al., Human Gene Therapy 6(11): 1417-1426 (Nov 1995)
193	PECORA, et al., Journal of Clinical Oncology, 20(9): 2251-2266 (May 1, 2002)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	
Examiner Name	

Sheet

7

of

8

Attorney Docket Number

CELL-004CON2

194	PETER, et al., Abstract No. P78, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002
195	RAMACHANDRA, et al., Nature Biotechnology, 19:1035-1041 (November 2001)
196	RENNIE, P. et al., Molec. Endocrinol. 7(1): 23-36 (1993)
197	RICCIO, A. et al., Nucleic Acids Res. 13(8): 2759-2771 (1985)
198	RICHARDS, C. et al., DNA Sequence-J. DNA Sequencing and Mapping, 4:185-196 (1993)
199	RICHARDS, C. et al., Human Gene Therapy 6:881-893 (1995)
200	RIEGMAN, P. et al., Molec. Endocrinol. 5(12):1921-1930 (1991)
201	RIES, et al., British Journal of Cancer, 86:5-11 (January 7, 2002)
202	RODRIGUEZ, R. et al., Cancer Res. 57:2559-2563 (1997)
203	RUSSELL, S., Eur. J. Cancer 30A: 1165-1171 (August 1994)
204	RUSSELL, W., Journal of General Virology, 81:2573-2604 (November 2000)
205	RYAN, et al., Eleventh International Conference on Gene Therapy of Cancer, San Diego, CA, December 12-14, 2002, 10(Suppl. 1): abstract No. 036
206	RYAN, et al., Abstract No. Or34, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002
207	SAMBROOK, J. et al., Cold Spring Harbor Laboratory Press, Table of Contents, pp. xi-xxxviii (1989)
208	SAUTHOFF, et al., Human Gene Therapy, 11:379-388 (February 10, 2000)
209	SCHEDLICH, L. et al., DNA 6(5): 429-437 (1987)
210	SCHREWE, H. et al., Mol. Cell. Biol. 10(6): 2738-2748 (1990)
211	SCHURR, E. et al., J. Biol. Chem. 271:7043-7051 (1996)
212	SHI, et al., Human Gene Therapy, 8:403-410 (March 1, 1997)
213	STEINWAERDER, et al., Gene Therapy, 7(7): 556-567 (April 2000)
214	STEWART, et al., Molecular Therapy, 5(5): abstract No. 53 (May 2002)
215	SWAMINATHAN, S., Curr. Topics in Microbiol. and Immunol. 199 Part 3:177-193 (1995)
216	TAL, M. et al., Mol. Cell. Biol. 7(7): 2597-2601 (1987)
217	TANEJA, S. et al., Proceedings of the American Association for Cancer Research 35:page 375, Abstract No. 2236 (1994)
208	TOLLEFSON, A. et al., J. Virol. 70(4): 2296-2306 (April 1996)
209	UENO, et al., Oncogene, 15:953-960 (1997)
220	VASSAUX, et al., Gene Therapy, 6:1192-1197 (1999)
221	VILE, et al., Cancer Gene Therapy, 9:1062-1067 (December 2002)

✓8

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

<b>Application Number</b>	10/822,873
<b>Filing Date</b>	April 13, 2004
<b>First Named Inventor</b>	Henderson et al.
<b>Group Art Unit</b>	
<b>Examiner Name</b>	

Sheet

8

of

8

Attorney Docket Number

CELL-004CON2

222	WEN, et al., Proceedings of the American Association for Cancer Research, 43:1098, abstract No. 5440 (March 2002)
223	WOLD, et al., Trends in Microbiology, 2(11): 437-443 (November 1994)
224	WOLD, et al., Curr. Top. Microbiol. Immunol., 199:237-274
225	WOLD, Virology, 184:1-8 (1991)
226	WOLD, et al., Current Opinion in Immunology, 11:380-386 (1999)
227	YOHN, et al., Journal of National Cancer Institute, 41:523-529 (1968)
228	YOUNG, C. et al., Biochem. 31(3): 818-824 (1992)
229	YU et al., Cancer Gene Therapy 8(9): 628-635 (Sep 2001)
230	YU H, et al., Cancer Research 55(10): 2104-2110 (May 15, 1995)
231	YU, DC et al. Cancer Research, 59(7): 1498-1504 (1999).
232	YU, et al., Cancer Research, 59:4200-4203 (September 1, 1999)
233	YU, et al., Cancer Research, 61:517-525 (January 15, 2001)
234	ZHANG, et al., Proceedings of the American Association for Cancer Research, 43:597, abstract No. 2955 (March 2002)
235	ZHANG, J. et al., Nucleic Acids Res. 25(15) 3143-3150 (1997)
236	ZHOU, ZHONG-XUN et al., Recent Progress in Hormone Research 49:249-274 (1994)
237	ZHU, et al., Molecular Therapy, 5(5):abstract No. 317 (May 2002)

Examiner Signature		Date Considered
-----------------------	--	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.